Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists
Diabetology
Curriculum:
Breaking Down the Barriers to Optimal Diabetes Outcomes
Breaking Down the Barriers to Optimal Diabetes Outcomes
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 09, 2014
December 09, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Internists, PCPs, nurses, pharmacists, NPs, and PAs involved in the management of patients with T2DM
Relevant Terms:
Type 2 Diabetes, GLP 1 agonist, Hypoglycemia, Weight, Injectable, Exenatide, Exenatide QW, Albiglutide, Liraglutide, Cardiovascular Risk
Zachary T. Bloomgarden, MD, MACE
Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Department of Medicine
Mount Sinai School of Medicine
New York, NY
Bio
Zachary T. Bloomgarden, MD, MACE is a clinician in private practice with an international reputation for writing and lecturing on diabetes, having authored more than 450 articles. He is Clinical Professor at Mount Sinai School of Medicine, and is Editor of the Journal of Diabetes.
Dr. Bloomgarden served on the Board of the American Association of Clinical Endocrinologists, the Journals Managing Subcommittee of the Endocrine Society, and the Editorial Board of Diabetes Care. The principal investigator for numerous studies, Dr. Bloomgarden was awarded the title of Master of the American College of Endocrinology in 2012. He has been listed for many years in the Castle Connolly Guide: The Best Doctors New York Metro Area.
Dr. Bloomgarden served on the Board of the American Association of Clinical Endocrinologists, the Journals Managing Subcommittee of the Endocrine Society, and the Editorial Board of Diabetes Care. The principal investigator for numerous studies, Dr. Bloomgarden was awarded the title of Master of the American College of Endocrinology in 2012. He has been listed for many years in the Castle Connolly Guide: The Best Doctors New York Metro Area.
Ellen Hirschman Miller, MD
Ellen Hirschman Miller, MD
Associate Professor of Medicine
Hofstra North Shore - LIJ School of Medicine
Hofstra University
Uniondale, NY
Bio
Ellen Hirschman Miller, MD is an Associate Professor of Medicine at the Hofstra North Shore-LIJ School of Medicine. She also has a private practice in internal medicine, endocrinology, and reproductive endocrinology in Hewlett, NY.
Dr. Miller received her medical degree from the New Jersey Medical School in 1980 and completed her post-graduate work at Beth Israel Medical Center and Columbia University. She is on the Editorial Board of Postgraduate Medicine, Physician and Sports Medicine, and Hospital Practice and is a Fellow of the American Association of Clinical Endocrinologists. Dr. Miller has conducted extensive research in the areas of endocrinology and women's health, and has authored articles that have been published in numerous medical journals.
Dr. Miller received her medical degree from the New Jersey Medical School in 1980 and completed her post-graduate work at Beth Israel Medical Center and Columbia University. She is on the Editorial Board of Postgraduate Medicine, Physician and Sports Medicine, and Hospital Practice and is a Fellow of the American Association of Clinical Endocrinologists. Dr. Miller has conducted extensive research in the areas of endocrinology and women's health, and has authored articles that have been published in numerous medical journals.
| 1. | Describe the relationships between glycemia and diabetes complications | 2. | Consider the HbA1c-lowering properties of GLP-1 agonists with their impacts on T2DM pathophysiology, CV risk factors, and hypoglycemic risk when individualizing treatment strategies for diabetic patients to reach target goals |
| 3. | Develop strategies to attain glycemic control throughout the life cycle of T2DM | 4. | Promote a collaborative approach to T2DM management, empowering the patient through individualized patient education to address and break down barriers for optimal outcomes, including adherence and injection-related barriers |
| 1. | Describe the relationships between glycemia and diabetes complications |
| 2. | Consider the HbA1c-lowering properties of GLP-1 agonists with their impacts on T2DM pathophysiology, CV risk factors, and hypoglycemic risk when individualizing treatment strategies for diabetic patients to reach target goals |
| 3. | Develop strategies to attain glycemic control throughout the life cycle of T2DM |
| 4. | Promote a collaborative approach to T2DM management, empowering the patient through individualized patient education to address and break down barriers for optimal outcomes, including adherence and injection-related barriers |
Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists
Program Overview/Statement of Need:
The most recent State of Health Care Quality Report, published by the National Committee for Quality Assurance (NCQA), indicated that only 43.2% of patients with diabetes had good HbA1c control (<7%), while 61.3% had an HbA1c of <8% and 28.5% had poor control (HbA1c >9%). Additional data show that many patients who reach their glycemic goal do not maintain it. Patients must become "partners in care," but more direction is needed to help clinicians successfully engage their patients.
Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists will guide internists, PCPs, nurses, pharmacists, NPs, and PAs through the practical application of up-to-date information in T2DM management and best practices to break down barriers preventing patients from reaching HbA1c goals. Clinicians will gain an improved understanding of the place of GLP-1 agonists in the treatment armamentarium; will be better able to differentiate the GLP-1 agonists currently available, including safety and efficacy profiles and injection delivery methods.
Target Audience: This activity is intended for internists, PCPs, nurses, pharmacists, NPs, and PAs involved in the management of patients with T2DM.
Learning Objectives:
After completion of this activity, participants should be able to:
- Describe the relationships between glycemia and diabetes complications
- Consider the HbA1c-lowering properties of GLP-1 agonists with their impacts on T2DM pathophysiology, CV risk factors, and hypoglycemic risk when individualizing treatment strategies for diabetic patients to reach target goals
- Develop strategies to attain glycemic control throughout the life cycle of T2DM
- Promote a collaborative approach to T2DM management, empowering the patient through individualized patient education to address and break down barriers for optimal outcomes, including adherence and injection-related barriers
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
Faculty Disclosures
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Zachary T. Bloomgarden, MD, MACE: Consultant/Advisor: AstraZeneca, Johnson & Johnson, Merck, Novartis, Novo Nordisk; Speaker: AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Merck, Novo Nordisk, Santaris Pharma; Stockholder: Baxter International, CVS Caremark, Novartis, Roche Holdings, St. Jude Medical
Ellen H. Miller, MD: Speaker: AstraZeneca
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Carole Drexel, PhD; Blair St. Amand; Jay Katz, CCMEP; Ashley Marostica, Joshua Kilbridge: Nothing to disclose
DISCLAIMER
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
PHYSICIAN CREDIT DESIGNATION
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from AstraZeneca.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 Credit™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 80% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
